SHANGHAI (Reuters) -U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.

“As part of our long-term strategy, we continue to align our resources to support evolving business needs across our global network,” a spokesperson for the company said in an emailed response to Reuters’ queries about a local media report.

The spokesperson said Bristol Myers was “committed to supporting all impacted employees” and was “grateful for their contributions”, but said it does not comment on transaction details, citing policy.

Established in 1982, the Sino-American Shanghai Squibb Pharmaceuticals Limited (SASS) joint venture was the first Sino-U.S. pharmaceutical joint venture in the country.

A manufact

See Full Page